Overview

Fluxergy creates a portable diagnostic platform that lets healthcare providers, veterinarians (including equine), and food-safety teams run multiple diagnostic tests on a single device, delivering rapid results at point-of-care. The system combines the device with disposable test kits to perform various tests, from molecular assays like COVID-19 to other health and safety checks, and is designed for fast, on-site decision-making. Fluxergy differentiates itself by offering industry-specific applications and a scalable, end-to-end solution (device plus kits) that targets diverse PoC settings, backed by partnerships and validated through collaborations with institutions such as Mass General Brigham. The company aims to expand production and adoption to set new benchmarks in how quickly and reliably laboratory testing can be done in real-world environments.

Simplify's Take

What believers are saying

• NIAID partnership enhances STI and vaginosis POC diagnostics on Fluxergy platform.
• EHV-1 PCR assay validated for equine testing, enabling in-house revenue retention.
• 70,000 sqft Irvine facility scales microfluidic manufacturing for growing demand.

What critics are saying

• Cepheid GeneXpert erodes market share with FDA-cleared STI panels in 6-12 months.
• BioFire FilmArray captures equine pathogen panels, outcompeting Fluxergy in 12-18 months.
• FDA clearance failure confines Fluxergy to veterinary markets in 12-24 months.

What makes Fluxergy unique

• Fluxergy's open platform runs molecular, immunoassay, chemistry, and cytometry on one analyzer.
• Portable FluxergySearch consolidates lab tests using fluorescence and imaging cytometry sensors.
• In-house PCR platform adopted in 80+ veterinary labs across US, Canada, and EU since 2022.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$49.5M

Below

Industry Average

Funded Over

3 Rounds

$30,000,000

Series C

May 2020

Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.

Series C Funding Comparison

Below Average

Industry standards

Ind Avg. $50M

$16M

$30M

$40M

$50M

$62M

$100M

View all funding stages